Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...

Adults may need support to manage their medicines safely and effectively, and for some people this will be provided as part of a home care service. When medicines support starts, tell the person’s GP ...

Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

have completed their Master of Public health (MPH) or individuals undertaking the portfolio route must have either passed their DFPH (Faculty of Public Health Diplomate Examination, formally Part A ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

Vamorolone (also called Agamree and made by Santhera), is an alternative to currently available corticosteroids used to reduce muscle inflammation and maintain muscle strength and function in people ...

NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...

Cisplatin is a powerful chemotherapy medicine which is routinely used to treat many cancers in children. Over time, cisplatin builds up in the inner ear and can cause inflammation and damage, known as ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

Our final draft guidance recommends elacestrant (also called KORSERDU and made by Menarini Stemline) for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) ...